![Shunichiro Okada](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Shunichiro Okada is currently Chief Medical Officer at Invea Therapeutics, Inc., a position held since 2022.
Education history includes undergraduate studies at The Johns Hopkins University and a doctorate from The University of Texas Southwestern Medical Center.
| Bedrijven | Functie | Begin |
|---|---|---|
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Hoofd Techniek/Wetenschap/O&O | 01-01-2022 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 3 |
|---|---|
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas Southwestern Medical Center
 The University of Texas Southwestern Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
